NCPC(SH:600812) Zheng Quan Zhi Xing·2025-08-13 12:08Core Viewpoint - North China Pharmaceutical (600812.SH) reported a significant increase in net profit for the first half of 2025, indicating strong operational improvements and cost management strategies [1] Financial Performance - The company achieved a revenue of 5.275 billion, representing a year-on-year growth of 0.84% [1] - Net profit attributable to shareholders reached 123 million, marking a year-on-year increase of 71.56% [1] - The net profit excluding non-recurring gains and losses was 120 million, showing a substantial growth of 120.69% year-on-year [1] - Basic earnings per share increased to 0.072 yuan [1] Operational Efficiency - The increase in total profit and net profit attributable to shareholders was primarily due to enhanced budget management, lean management practices, and overall quality and efficiency improvements [1] - The company successfully reduced procurement costs and various expenses, thereby improving profitability [1] - The significant increase in net profit, along with a large reduction in non-recurring gains and losses compared to the previous year, contributed to the rise in net profit excluding non-recurring items [1] Cash Flow - The net cash flow from operating activities decreased, primarily due to the receipt of land compensation of 410 million from the Shijiazhuang Land Reserve Center in the first half of 2024 [1]